Protea Biosciences Group, Inc. 4

4 · Protea Biosciences Group, Inc. · Filed Nov 5, 2014

Form 4

Period: 2014-10-31

Director

Transactions

Conversion
Warrant
2014-10-31+339,388→ 1,793,069 total
Exercise: $0.38From: 2014-10-31Exp: 2017-10-31→ Common Stock (339,388 underlying)
Conversion
Series A Convertible Preferred Stock
2014-10-31+84,847→ 84,847 total
→ Common Stock (678,776 underlying)
Conversion
Convertible Note
2014-10-31
From: 2014-10-31Exp: 2014-10-31→ Series A Convertible Preferred Stock & Warrants

Footnotes (2)

[F1]The Issuer issued Series A Convertible Preferred Stock (the "Preferred Stock") in connection with the conversion of $169,696 outstanding principal and accrued unpaid interest of certain covertible promissory notes (the "Notes") to Leonard Harris (the "Reporting Person"). Each share of Preferred Stock has a stated value equal to $2.00, subject to increase based on the accrual of a 6% dividend (the "Stated Value"). The Preferred Stock will automatically convert into shares of Common Stock determined by dividing the Stated Value by $0.25 per share on February 17, 2015, subject to extension.
[F2]In connection with the conversion of the Notes, the Reporting Person also received a 3 year warrant to purchase 339,388 shares of the Company's common stock, exercisable at $0.375 per share.

Documents

1 file